朱海涛,刘哲豪
ZHU Haitao,LIU Zhehao

• 1:贵州医科大学附院肝胆外科

摘要(Abstract)：

目的:探讨多发与单发乙肝相关肝细胞癌根治术后的复发率和总生存率。方法:回顾性分析28例乙肝相关肝细胞癌患者的随访资料,多发瘤患者15例(多发瘤组)和单发瘤患者13例(单发瘤组),所有患者均已行肝癌根治术,术后平均随访时间为18.1个月,术后每3个月随访1次,比较2组患者根治术后随访期内的复发率与总生存率。结果:单发瘤组患者术后复发率低于多发瘤组患者,总生存率高于多发瘤组患者,差异有统计学意义(P<0.05)。结论:单发乙肝相关性肝细胞癌患者根治术后预后优于多发肿瘤患者。
Objective: To investigate the overall survival( OS) and time to recurrence( TTR) between multiple-nodular and single-nodular Hepatitis B virus( HBV)-related hepatocellular carcinoma( HCC) after radical resection. Methods: Retrospective analysis on follow up record of 28 HBV-related HCC patients. All patients received radical resection as the treatment of HCC. 15 were multiplenodular HCC patients( multiple-nodular group),13 were single-nodular HCC patients( single-nodular group). Average follow up time is 18. 1 months after surgery,once in every three months. Overall survival rate and time to recurrence rate were analyzed between both groups. Results: The TTR of singlenodular group was lower than that of multiple-nodular group,while OS was higher than that of multiplenodular HCC group,differences were statistically significant( P < 0. 05). Conclusion: The prognosis after radical resection of single-nodular HCC patients was better than that of multiple-nodular HCC patients.

关键词(KeyWords)： 癌,肝细胞;肝炎,乙型;随访研究;肝癌根治术;复发率;生存率
carcinoma,hepatocellular;hepatitis B-virus;Follow up study;radical resection of liver cancer;recurrence rate;survival rate

Abstract:

Keywords:

基金项目(Foundation): 贵州省科技计划项目[黔科合LH字(2016)7232号]

作者(Author): 朱海涛,刘哲豪
ZHU Haitao,LIU Zhehao

DOI: 10.19367/j.cnki.1000-2707.2018.07.016

参考文献(References)：

• [1]JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
• [2]董伟,刘福晨,倪俊声,等.氟尿嘧啶联合姜黄素纳米剂型抑制肝癌细胞的研究[J].中国现代医学杂志,2016,26(9):16-22.
• [3]DAHER S,MASSARWA M,BENSON A A,et al.Current and future treatment of hepatocellular carcinoma:An updated comprehensive review[J].J Clin Transl Hepatol,2018,6(1):69-78.
• [4]郭云韬,喻超,陈礼闻,等.siRNA干扰沉默NUF2基因对肝癌HCCLM3细胞迁移和侵袭的影响[J].贵州医科大学学报,2017,42(2):147-150.
• [5]DIMITROULIS D,DAMASKOS C,VALSAMI S,et al.From diagnosis to treatment of hepatocellular carcinoma:An epidemic problem for both developed and developing world[J].World J Gastroenterol,2017,23(29):5282-5294.
• [6]OHKUBO T,MIDORIKAWA Y,NAKAYAMA H,et al.Liver resection of hepatocellular carcinoma in patients with portal hypertension and multiple tumors[J].Hepatol Res,2018,48(6):433-441.
• [7]YASUDA S,NOMI T,HOKUTO D,et al.Huge hepatocellular carcinoma with multiple intrahepatic metastases:An aggressive multimodal treatment[J].Int J Surg Case Rep,2015,16:44-47.
• [8]BRUIX J,GORES G J,MAZZAFERRO V.Hepatocellular carcinoma:Clinical frontiers and perspectives[J].Gut,2014,63(5):844-855.
• [9]POON R T,FAN S T,NG I O,et al.Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma[J].Cancer,2000,89(3):500-507.
• [10]WANG Z J,WANG M Q,DUAN F,et al.Clinical application of transcatheter arterial chemoembolization combined with synchronous C-arm cone-beam CT guided radiofrequency ablation in treatment of large hepatocellular carcinoma[J].Asian Pac J Cancer Prev,2013,14(3):1649-1654.
• [11]XUE R,LI R,GUO H,et al.Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma[J].Gastroenterology,2016,150(4):998-1008.
• [12]XING X,HUANG Y,WANG S,et al.Comparative analysis of primary hepatocellular carcinoma with single and multiple lesions by i TRAQ-based quantitative proteomics[J].J Proteomics,2015,128:262-271.

文章评论(Comment)：